Filtered By:
Infectious Disease: Outbreaks
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 16 results found since Jan 2013.
Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis
CONCLUSIONS: The evidence for the seven specified outcomes was of low or very low certainty due to imprecision and high risk of bias. The evidence that antiviral agents shorten the duration of symptoms or signs when compared with artificial tears was inconclusive. Low certainty evidence suggests that PVP-I alone resolves signs and symptoms by seven days relative to artificial tears. PVP-I or PVA-I, alone or with steroid, is associated with lower risks of SEI development than artificial tears or steroid (very low certainty evidence). The currently available evidence is insufficient to determine whether any of the evaluated ...
Source: Cochrane Database of Systematic Reviews - March 3, 2022 Category: General Medicine Authors: Su-Hsun Liu Barbara S Hawkins Sueko M Ng Mark Ren Louis Leslie Genie Han Irene C Kuo Source Type: research
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study
CONCLUSIONS: This study has shown the therapeutic benefits of NEPA in the management and prophylaxis of CINV events, both in naive patients and patients previously treated with 5HT3-RA and NK1-RA. In addition, NEPA has been shown to be safe, both before and during the COVID-19 pandemic.PMID:34486707 | DOI:10.26355/eurrev_202108_26552
Source: Pharmacological Reviews - September 6, 2021 Category: Drugs & Pharmacology Authors: R De Luca C Volpe O Mistretta R Paci G Ferrera V Caputo G Rosati G Cicero Source Type: research
Immunomodulatory role and potential utility of various nutrients and dietary components in SARS-CoV-2 infection
Int J Vitam Nutr Res. 2021 Jun 8:1-14. doi: 10.1024/0300-9831/a000715. Online ahead of print.ABSTRACT Recently, the outbreak of severe acute respiratory syndrome cornoavirus-2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has become a great perturbation all around the globe and has many devastating effects on every aspect of life. Apart from the oxygen therapy and extracorporeal membrane oxygenation, Remdesivir and Dexamethasone have been proven to be efficacious against COVID-19, along with various vaccine candidates and monoclonal antibody cocktail therapy for Regeneron. All of these are currently at differe...
Source: International Journal for Vitamin and Nutrition Research - June 8, 2021 Category: Nutrition Authors: Muhammad Osama Yaseen Humzah Jamshaid Arifa Saif Talib Hussain Source Type: research
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19
Brief Bioinform. 2021 May 1:bbab114. doi: 10.1093/bib/bbab114. Online ahead of print.ABSTRACTThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is undeniably the most severe global health emergency since the 1918 Influenza outbreak. Depending on its evolutionary trajectory, the virus is expected to establish itself as an endemic infectious respiratory disease exhibiting seasonal flare-ups. Therefore, despite the unprecedented rally to reach a vaccine that can offer widespread immunization, it is equally important to reach effective prevention and treatment regimens for coronavirus disease 2019 (COVID...
Source: Briefings in Bioinformatics - May 19, 2021 Category: Bioinformatics Authors: M Tomazou M M Bourdakou G Minadakis M Zachariou A Oulas E Karatzas E Loizidou A Kakouri C Christodoulou K Savva M Zanti A Onisiforou S Afxenti J Richter C G Christodoulou T Kyprianou G Kolios N Dietis G M Spyrou Source Type: research
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
Biomed Pharmacother. 2021 Apr 27;139:111642. doi: 10.1016/j.biopha.2021.111642. Online ahead of print.ABSTRACTCOVID-19 is announced as a global pandemic in 2020. Its mortality and morbidity rate are rapidly increasing, with limited medications. The emergent outbreak of COVID-19 prompted by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps spreading. In this infection, a patient's immune response plays pivotal role in the pathogenesis. This inflammatory factor was shown by its mediators that, in severe cases, reach the cytokine at peaks. Hyperinflammatory state may sparks significant imbalances in transport...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 3, 2021 Category: Drugs & Pharmacology Authors: Devendra Kumar Neerja Trivedi Source Type: research
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
ConclusionDosing of drugs used to treat COVID-19 in patients with renal or hepatic impairment is complex. These recommendations were produced to provide guidance to clinicians worldwide who are treating patients with COVID-19, many of whom will have some degree of acute or chronic renal or hepatic impairment.
Source: Drugs in R&D - December 17, 2020 Category: Drugs & Pharmacology Source Type: research
TWiV 629: Coronavirus update, pandemic sitrep
Daniel Griffin provides a clinical update on COVID-19, including analysis of the dexamethasone trial, and then we discuss two Ebolavirus outbreaks in DRC, clinical and virological aspects of asymptomatic SARS-CoV-2 infections, age-dependent effects on transmission, and answer listener email. Click arrow to playDownload TWiV 629 (95 MB .mp3, 158 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes […]
Source: virology blog - June 24, 2020 Category: Virology Authors: Vincent Racaniello Tags: This Week in Virology age dependent effects clinical outcomes coronavirus COVID-19 dexamethasone ebolavirus pandemic SARS-CoV-2 transmission viral viruses Source Type: blogs
